InsiderTrades

Form 4 for KEQU KEWAUNEE SCIENTIFIC CORP /DE/

Accepted 2024-07-16 00:00:00 ET · period of report 2024-07-16 · accession 0001657070-24-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-07-16 2024-07-16 KEQU HULL THOMAS DAVID III Pres, CEO, Dir F - Tax $52.00 -7,877 46.5K -14% -$409.6K
DM 2024-07-16 2024-07-16 KEQU HULL THOMAS DAVID III Pres, CEO, Dir M - OptEx $20.13 +12.0K 48.4K +33% +$241.6K
DM 2024-07-16 2024-07-16 KEQU HULL THOMAS DAVID III Pres, CEO, Dir M - OptEx — -12.0K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-07-16 F D 7,877 $52.00 46,497 D — — (F1) Consideration for the exercise of the underlying option to buy was paid through a "net exercise" by directing the company to retain as payment for the total exercise cost a sufficient number of shares of Common Stock that would have been otherwise received upon exercise as reported below on this Form 4 report. (F2) Also includes shares withheld by the company to discharge withholding tax obligations of the reporting person.
2 Common Common Stock 2024-07-16 M A 6,000 $23.62 54,374 D — — (F1) Consideration for the exercise of the underlying option to buy was paid through a "net exercise" by directing the company to retain as payment for the total exercise cost a sufficient number of shares of Common Stock that would have been otherwise received upon exercise as reported below on this Form 4 report.
3 Common Common Stock 2024-07-16 M A 6,000 $16.64 48,374 D — — (F1) Consideration for the exercise of the underlying option to buy was paid through a "net exercise" by directing the company to retain as payment for the total exercise cost a sufficient number of shares of Common Stock that would have been otherwise received upon exercise as reported below on this Form 4 report.
4 Derivative Option to Buy FY17 2024-07-16 M D 6,000 — 0 D $23.62 · 2020-08-31 to 2026-08-31 6,000 Common Stock (F3) Employee stock option granted under Employee Stock Option plan under Rule 16b-3.
5 Derivative Option to Buy 2024-07-16 M D 6,000 — 0 D $16.64 · 2019-11-02 to 2025-11-02 6,000 Common Stock (F3) Employee stock option granted under Employee Stock Option plan under Rule 16b-3.